Table 4.
Comparison of ORR in subgroup analysis
| Items | M1 | M3 | M6 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CSM-TACE group | cTACE group | P value | CSM-TACE group | cTACE group | P value | CSM-TACE group | cTACE group | P value | |
| Number of assessed patients | 107 | 124 | 82 | 55 | 54 | 45 | |||
| Age (n/%) | |||||||||
| ≥60 years | 29 (80.6) | 23 (48.9) | 0.007 | 19 (70.4) | 16 (64.0) | 0.652 | 17 (81.0) | 11 (52.4) | 0.050 |
| <60 years | 48 (67.6) | 35 (45.5) | 0.003 | 44 (80.0) | 9 (30.0) | <0.001 | 21 (63.6) | 10 (41.7) | 0.100 |
| Gender (n/%) | |||||||||
| Male | 68 (71.6) | 55 (47.8) | 0.001 | 49 (74.2) | 21 (12.9) | 0.001 | 34 (75.6) | 19 (45.2) | 0.004 |
| Female | 9 (75.0) | 3 (33.3) | 0.056 | 14 (87.5) | 4 (66.7) | 0.259 | 4 (44.4) | 2 (66.7) | 0.505 |
| Largest nodule size≥7cm (n/%) | |||||||||
| Yes | 43 (69.4) | 24 (44.4) | 0.007 | 26 (63.4) | 10 (43.5) | 0.123 | 16 (64.0) | 5 (35.7) | 0.089 |
| No | 34 (75.6) | 34 (78.6) | 0.004 | 37 (90.2) | 15 (46.9) | <0.001 | 22 (75.9) | 16 (51.6) | 0.051 |
| Portal vein invasion (n/%) | |||||||||
| Yes | 29 (82.9) | 15 (50.0) | 0.005 | 21 (75.0) | 6 (40.0) | 0.024 | 12 (66.7) | 1 (12.5) | 0.011 |
| No | 48 (66.7) | 43 (45.7) | 0.007 | 42 (77.8) | 19 (47.5) | 0.002 | 26 (72.2) | 20 (54.1) | 0.108 |
| Hepatic vein invasion (n/%) | |||||||||
| Yes | 12 (66.7) | 7 (43.8) | 0.179 | 7 (63.6) | 5 (52.5) | 0.960 | 3 (42.9) | 3 (75.0) | 0.303 |
| No | 65 (73.0) | 51 (47.2) | <0.001 | 56 (78.9) | 20 (42.6) | <0.001 | 35 (74.5) | 18 (43.9) | 0.003 |
| Child-pugh Stage (n/%) | |||||||||
| A | 65 (75.6) | 68 (46.6) | <0.001 | 52 (77.6) | 19 (42.2) | <0.001 | 33 (70.2) | 18 (46.2) | 0.024 |
| B/C | 12 (57.1) | 10 (47.6) | 0.537 | 11 (73.3) | 6 (60.0) | 0.484 | 5 (71.4) | 3 (50.0) | 0.429 |
| BCLC Stage (n/%) | |||||||||
| A/B | 44 (66.7) | 39 (46.4) | 0.013 | 39 (78.0) | 16 (43.2) | 0.001 | 24 (70.6) | 17 (50.0) | 0.083 |
| C/D | 33 (80.5) | 19 (47.5) | 0.002 | 24 (75.0) | 9 (50.0) | 0.073 | 14 (70.0) | 4 (36.4) | 0.069 |
| AFP (n/%)# | |||||||||
| ≥120.5 μg/L | 43 (71.7) | 24 (46.2) | 0.006 | 31 (75.6) | 9 (37.5) | 0.002 | 20 (66.7) | 7 (36.8) | 0.041 |
| <120.5 μg/L | 27 (69.2) | 29 (49.2) | 0.049 | 28 (80.0) | 13 (50.0) | 0.014 | 16 (80.0) | 13 (52.0) | 0.051 |
Notes: Data were presented as count (%). Comparison between 2 groups was determined by Chi-square test. P value <0.05 was considered significant, and the significant results were shown in boldface. #: AFP was divided by median value (120.5 μg/L). ORR, objective response rate; CSM-TACE, transarterial chemoembolization with CalliSpheres® microspheres; cTACE, conventional transarterial chemo-embolization; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein.